Resmetirom (metabolic dysfunction-associated steatohepatitis) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Resmetirom (metabolic dysfunction-associated steatohepatitis) – Benefit assessment according to §35a Social Code Book V

   published on

   15.12.2025

   Document type

   PDF document, 694 kB, EN, not accessible

   DOI-Link

   https://doi.org/10.60584/A25-117_en

   Download file : Extract of dossier assessment (PDF document, 694 kB, EN, not accessible)
2. Dossier assessment

   Resmetirom (metabolic dysfunction-associated steatohepatitis) – Benefit assessment according to §35a Social Code Book V

   published on

   15.12.2025

   Document type

   PDF document, 1 MB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A25-117

   Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Additional information

Project details

Project no.

A25-117

Commission

Commission awarded on 15.09.2025 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Digestion, metabolism and hormones

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-117_en

Connected Projects

1. Addendum

   Resmetirom (metabolic dysfunction-associated steatohepatitis) – Addendum to Project A25-117

   Project no.

   A26-08

   Last updated

   05.03.2026

   Status: Commission completed